BridgeBio Oncology reports Q2 2026 results, starts two KRAS inhibitor combination trials
BBOT dosed BBO-11818 with BBO-10203 after the quarter closed and said cash covers operations into 2028.
SEC filing
Latest
1 story
Sign inSign in1 story
BBOT dosed BBO-11818 with BBO-10203 after the quarter closed and said cash covers operations into 2028.
SEC filing